162 related articles for article (PubMed ID: 18936438)
21. Treatment with human chorionic gonadotropin and risk of breast cancer.
Bernstein L; Hanisch R; Sullivan-Halley J; Ross RK
Cancer Epidemiol Biomarkers Prev; 1995; 4(5):437-40. PubMed ID: 7549796
[TBL] [Abstract][Full Text] [Related]
22. Vaginal fluid creatinine, human chorionic gonadotropin and alpha-fetoprotein levels for detecting premature rupture of membranes.
Li HY; Chang TS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Sep; 63(9):686-90. PubMed ID: 11037644
[TBL] [Abstract][Full Text] [Related]
23. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
24. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
25. [Dependence of the concentration of maternal serum markers on the haptoglobin gene].
Chivilev IV; Zolotukhina TV; Spitsyn VA; Nurbaev SD; Gribkova LG
Genetika; 1997 Mar; 33(3):399-404. PubMed ID: 9244773
[TBL] [Abstract][Full Text] [Related]
26. Intrahepatic cholestasis of pregnancy has no effect on maternal serum second trimester alpha-fetoprotein and hCG.
Eloranta ML; Heinonen S; Kirkinen P
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):548-52. PubMed ID: 10929953
[TBL] [Abstract][Full Text] [Related]
27. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein.
Benn PA; Horne D; Briganti S; Rodis JF; Clive JM
Obstet Gynecol; 1996 Feb; 87(2):217-22. PubMed ID: 8559527
[TBL] [Abstract][Full Text] [Related]
28. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
30. Maternal serum hCG, PAPP-A and AFP as predictors of hemoglobin Bart disease at mid-pregnancy.
Tongprasert F; Wanapirak C; Tongsong T
Prenat Diagn; 2011 May; 31(5):430-3. PubMed ID: 21312197
[TBL] [Abstract][Full Text] [Related]
31. [Relation of gestational age, maternal body weight and age or serum alpha-fetoprotein and human chorionic gonadotropin at second-trimester].
Natori M; Tanaka M; Ishimoto H; Gohda N; Kiyokawa K; Yamauchi J; Miyazaki T; Kobayashi T; Nozawa S; Takagi T
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jul; 46(7):562-6. PubMed ID: 7522264
[TBL] [Abstract][Full Text] [Related]
32. Maternal concentrations of human chorionic gonadotropin (hCG) and risk for cerebral palsy (CP) in the child. A case control study.
Eskild A; Monkerud L; Jukic AM; Åsvold BO; Lie KK
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():203-208. PubMed ID: 30007247
[TBL] [Abstract][Full Text] [Related]
33. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening.
Palomaki GE; Knight GJ; Haddow JE; Canick JA; Wald NJ; Kennard A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):675-8. PubMed ID: 7682315
[TBL] [Abstract][Full Text] [Related]
34. alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence.
Melbye M; Wohlfahrt J; Lei U; Nørgaard-Pedersen B; Mouridsen HT; Lambe M; Michels KB
J Natl Cancer Inst; 2000 Jun; 92(12):1001-5. PubMed ID: 10861312
[TBL] [Abstract][Full Text] [Related]
35. Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions.
Salim R; Okopnik M; Garmi G; Nachum Z; Zafran N; Shalev E
Placenta; 2010 Apr; 31(4):277-81. PubMed ID: 20132984
[TBL] [Abstract][Full Text] [Related]
36. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
[TBL] [Abstract][Full Text] [Related]
37. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
38. Second trimester maternal serum markers and a predictive model for predicting fetal hemoglobin Bart's disease.
Tongprasert F; Srisupundit K; Luewan S; Tongsong T
J Matern Fetal Neonatal Med; 2013 Jan; 26(2):146-9. PubMed ID: 22989193
[TBL] [Abstract][Full Text] [Related]
39. Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.
Toriola AT; Tolockiene E; Schock H; Surcel HM; Zeleniuch-Jacquotte A; Wadell G; Toniolo P; Lundin E; Grankvist K; Lukanova A
Future Oncol; 2014 Feb; 10(3):377-84. PubMed ID: 24559445
[TBL] [Abstract][Full Text] [Related]
40. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications.
Gonen R; Perez R; David M; Dar H; Merksamer R; Sharf M
Obstet Gynecol; 1992 Jul; 80(1):83-6. PubMed ID: 1603504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
